Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 9/20 | 0.74 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.74 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.74 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.74 |
| ▸ | CCNB2 | O95067 | 7/20 | 0.74 |
| ▸ | CDK1 | P06493 | 7/20 | 0.74 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.74 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 0.74 |
| ▸ | RAF1 | P04049 | 4/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.74 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.74 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.74 |
| ▸ | PRKCG | P05129 | 3/20 | 0.74 |
| ▸ | PRKCB | P05771 | 3/20 | 0.74 |
| ▸ | PRKCA | P17252 | 3/20 | 0.74 |
| ▸ | PRKCH | P24723 | 3/20 | 0.74 |
| ▸ | PRKCI | P41743 | 3/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.74 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.74 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hymenialdisine SCHEMBL1249687 | 1.00 | CHEK2 (0.74) | CHEK2CDK5CDK5R1CHEK1CCNB2 | |
| Hymenialdisine SCHEMBL155899 | 1.00 | CHEK2 (0.74) | CHEK2CDK5CDK5R1CHEK1CCNB2 | |
| Hymenialdisine SCHEMBL6031276 | 0.96 | CDK5 (0.69) | CHEK2CDK5CDK5R1CHEK1CCNB2 | |
| Hymenialdisine SCHEMBL20720488 | 0.90 | CHEK2 (0.61) | CHEK2CDK5CDK5R1CHEK1CCNB2 | |
| Hymenialdisine SCHEMBL15426167 | 0.85 | CDK5 (1.00) | CHEK2CDK5CDK5R1CHEK1CCNB2 | |
| Hymenialdisine SCHEMBL18114524 | 0.85 | CDK5 (1.00) | CHEK2CDK5CDK5R1CHEK1CCNB2 | |
| Debromohymenialdisine SCHEMBL3577997 | 0.79 | CDK5 (0.70) | CHEK2CDK5CDK5R1CHEK1CCNB2 | |
| Debromohymenialdisine SCHEMBL4303192 | 0.79 | CDK5 (0.70) | CHEK2CDK5CDK5R1CHEK1CCNB2 | |
| Debromohymenialdisine SCHEMBL3578000 | 0.79 | CDK5 (0.70) | CHEK2CDK5CDK5R1CHEK1CCNB2 | |
| Spongiacidin D SCHEMBL15426068 | 0.78 | CDK5 (1.00) | CHEK2CDK5CDK5R1CHEK1CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399602-A1 | Method for Differentiation of Human Pluripotent Stem Cell Lines in Suspension Culture | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-24 | — | — | US | claimed |
| CN-112041428-A | Method for differentiating human pluripotent stem cell lines in suspension culture | 新加坡科技研究局 | 2020-12-04 | — | — | CN | claimed |
| EP-3740566-A1 | METHOD FOR DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELL LINES IN SUSPENSION CULTURE | Agency for Science, Technology and Research (SG) | 2020-11-25 | — | — | EP | claimed |
| WO-2019143292-A1 | METHOD FOR DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELL LINES IN SUSPENSION CULTURE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-07-25 | — | — | WO | claimed |
| US-20170252449-A1 | SOLUBILIZED COMPOSITIONS FOR CONTROLLED PROLIFERATION OF STEM CELLS / GENERATING INNER EAR HAIR CELLS USING GSK3 INHIBITORS: III | Frequency Therapeutics, Inc. | 2017-09-07 | — | — | US | claimed |
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2009-12-17 | — | — | US | claimed |
| US-20070196514-A1 | Prostate cancer treatment with glycogen synthase kinase-3beta inhibitors | UNIVERSITY OF KANSAS MEDICAL CENTER | 2007-08-23 | — | — | US | claimed |
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | NOVARTIS AG (CH) | 2004-09-23 | — | — | US | claimed |
| EP-1106180-B1 | Use of hymenialdisine or derivatives thereof in the manufacture of medicaments | CENTRE NAT RECH SCIENT (FR) | 2003-11-12 | — | — | EP | claimed |
| EP-0630245-B1 | PROTEIN KINASE C INHIBITOR | SMITHKLINE BEECHAM CORP (US) | 1999-01-20 | — | — | EP | claimed |
| US-5616577-A | Protein Kinase C inhibitor | SMITHKLINE BEECHAM CORPORATION | 1997-04-01 | — | — | US | claimed |
| US-5565448-A | Medicament | SMITHKLINE BEECHAM CORPORATION (US) | 1996-10-15 | — | — | US | claimed |
| EP-0630245-A1 | PROTEIN KINASE C INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-28 | — | — | EP | claimed |
| EP-0630245-A4 | PROTEIN KINASE C INHIBITOR. | SMITHKLINE BEECHAM CORP (US) | 1994-11-02 | — | — | EP | claimed |
| WO-1993016703-A1 | PROTEIN KINASE C INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-02 | — | — | WO | claimed |
| US-20250114470-A1 | THERAPY FOR POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF MASSACHUSETTS | 2025-04-10 | — | — | US | disclosed |
| US-20250108070-A1 | METHOD FOR REPROGRAMMING CD8+ T CELLS TO ENHANCE THEIR THERAPEUTIC POTENTIAL AND APPLICATIONS THEREOF | INSTITUT PASTEUR (FR) | 2025-04-03 | — | — | US | disclosed |
| EP-0630245-A1 | PROTEIN KINASE C INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-28 | — | — | EP | disclosed |
| EP-0630245-A4 | PROTEIN KINASE C INHIBITOR. | SMITHKLINE BEECHAM CORP (US) | 1994-11-02 | — | — | EP | disclosed |
| WO-1993016703-A1 | PROTEIN KINASE C INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186159-A1 | Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma | GSK3B, GSK3A, GSKIP | CHEK2 1443/4885CDK5 367/4885CDK5R1 778/4885 |
| US-20250108070-A1 | METHOD FOR REPROGRAMMING CD8+ T CELLS TO ENHANCE THEIR THERAPEUTIC POTENTIAL AND APPLICATIONS THEREOF | ICOS, CD4, NFATC1 | CHEK2 2779/4885CDK5 4454/4885CDK5R1 4239/4885 |
| US-20090312390-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA | GSK3B, GSK3A, GSKIP | CHEK2 1443/4885CDK5 367/4885CDK5R1 778/4885 |
| US-20170252449-A1 | SOLUBILIZED COMPOSITIONS FOR CONTROLLED PROLIFERATION OF STEM CELLS / GENERATING INNER EAR HAIR CELLS USING GSK3 INHIBITORS: III | GSK3B, GSK3A, GSKIP | CHEK2 855/4885CDK5 113/4885CDK5R1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.